{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:21:16Z","timestamp":1791195676864,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006738","name":"Lund University Faculty of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004635","name":"Mrs Berta Kamprad foundation for exploration and combat cancer","doi-asserted-by":"publisher","award":["FBKS-2021-29"],"award-info":[{"award-number":["FBKS-2021-29"]}],"id":[{"id":"10.13039\/501100004635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["22 2203 Pj 01H"],"award-info":[{"award-number":["22 2203 Pj 01H"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["21 1836 Pj"],"award-info":[{"award-number":["21 1836 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut and Alice Wallenberg Foundation","doi-asserted-by":"publisher","award":["2023.0073"],"award-info":[{"award-number":["2023.0073"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut and Alice Wallenberg Foundation","doi-asserted-by":"publisher","award":["2023.0512"],"award-info":[{"award-number":["2023.0512"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003252","name":"Lunds Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009751","name":"Franke and Margareta Bergqvist Foundation for the Advancement of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003849","name":"IngaBritt and Arne Lundberg Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003849","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2020-04478"],"award-info":[{"award-number":["2020-04478"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2018-06228"],"award-info":[{"award-number":["2018-06228"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005753","name":"Royal Physiographic Society of Lund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005753","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jconrel.2025.02.047","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T12:58:27Z","timestamp":1740661107000},"page":"113551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Optimizing peptide nucleic acid-based pretargeting for enhanced targeted radionuclide therapy"],"prefix":"10.1016","volume":"381","author":[{"given":"Mohamed","family":"Altai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1bel","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Granit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wahed","family":"Zedan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Cerezo-Maga\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"L\u00fcckerath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Geres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Sydoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.J.","family":"Thorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Westerlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ulmert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie Eriksson","family":"Karlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jconrel.2025.02.047_bb0005","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/nbt1141","article-title":"Arming antibodies: prospects and challenges for immunoconjugates","volume":"23","author":"Wu","year":"2005","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.jconrel.2025.02.047_bb0010","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3390\/ph17040508","article-title":"Approaches to reducing normal tissue radiation from radiolabeled antibodies","volume":"17","author":"Suzuki","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"10","key":"10.1016\/j.jconrel.2025.02.047_bb0015","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2967\/jnumed.117.189944","article-title":"Pretargeted imaging and therapy","volume":"58","author":"Altai","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.jconrel.2025.02.047_bb0020","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.2967\/jnumed.121.262186","article-title":"Pretargeting: a path forward for radioimmunotherapy","volume":"63","author":"Cheal","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2025.02.047_bb0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1040-8428(01)00133-0","article-title":"Pretargeted radioimmunotherapy (PRIT\u2122) for treatment of non-Hodgkin\u2019s lymphoma (NHL)","volume":"40","author":"Weiden","year":"2001","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.02.047_bb0030","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.bjc.6600047","article-title":"Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: a pilot study","volume":"86","author":"Grana","year":"2002","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2025.02.047_bb0035","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2003-09-3284","article-title":"Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma","volume":"104","author":"Forero","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jconrel.2025.02.047_bb0040","first-page":"867","article-title":"Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding","volume":"36","author":"Sung","year":"1995","journal-title":"J. Nucl. Med."},{"issue":"11","key":"10.1016\/j.jconrel.2025.02.047_bb0045","first-page":"1791","article-title":"Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication","volume":"31","author":"Kalofonos","year":"1990","journal-title":"J. Nucl. Med."},{"issue":"7","key":"10.1016\/j.jconrel.2025.02.047_bb0050","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1158\/1535-7163.MCT-13-0933","article-title":"Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex","volume":"13","author":"Cheal","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"NOV","key":"10.1016\/j.jconrel.2025.02.047_bb0055","article-title":"Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry","volume":"1","author":"van de Watering","year":"2014","journal-title":"Front. Med. (Lausanne)"},{"issue":"2","key":"10.1016\/j.jconrel.2025.02.047_bb0060","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/1078-0432.CCR-20-2150","article-title":"A self-assembling and disassembling (SADA) bispecific antibody (BsAb) platform for curative two-step pretargeted radioimmunotherapy","volume":"27","author":"Santich","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"45","key":"10.1016\/j.jconrel.2025.02.047_bb0065","doi-asserted-by":"crossref","first-page":"28316","DOI":"10.1073\/pnas.2009960117","article-title":"Harnessing 64Cu\/67Cu for a theranostic approach to pretargeted radioimmunotherapy","volume":"117","author":"Kein\u00e4nen","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.jconrel.2025.02.047_bb0070","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1021\/acs.molpharmaceut.8b00093","article-title":"Click-mediated pretargeted radioimmunotherapy of colorectal carcinoma","volume":"15","author":"Membreno","year":"2018","journal-title":"Mol. Pharm."},{"issue":"9","key":"10.1016\/j.jconrel.2025.02.047_bb0075","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.2967\/jnumed.120.260687","article-title":"Current landscape in clinical pretargeted radioimmunoimaging and therapy","volume":"62","author":"Jallinoja","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"MAR","key":"10.1016\/j.jconrel.2025.02.047_bb0080","article-title":"A pretargeting system for tumor PET imaging and radioimmunotherapy","volume":"6","author":"Kraeber-Bod\u00e9r\u00e9","year":"2015","journal-title":"Front. Pharmacol."},{"issue":"S12","key":"10.1016\/j.jconrel.2025.02.047_bb0085","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2699::AID-CNCR48>3.0.CO;2-4","article-title":"Pretargeting using peptide nucleic acid","volume":"80","author":"Rusckowski","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2025.02.047_bb0090","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.biomaterials.2019.02.012","article-title":"Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting","volume":"203","author":"Westerlund","year":"2019","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.jconrel.2025.02.047_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-27886-0","article-title":"Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy","volume":"8","author":"Vorobyeva","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2025.02.047_bb0100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.7150\/thno.12766","article-title":"Feasibility of affibody molecule-based PNA-mediated radionuclide pretargeting of malignant tumors","volume":"6","author":"Honarvar","year":"2016","journal-title":"Theranostics"},{"issue":"10","key":"10.1016\/j.jconrel.2025.02.047_bb0105","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1039\/C5SC00951K","article-title":"In vivo demonstration of an active tumor pretargeting approach with peptide nucleic acid bioconjugates as complementary system","volume":"6","author":"Leonidova","year":"2015","journal-title":"Chem. Sci."},{"issue":"7","key":"10.1016\/j.jconrel.2025.02.047_bb0110","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.2967\/jnumed.121.262123","article-title":"Affibody-mediated PNA-based pretargeted cotreatment improves survival of trastuzumab-treated mice bearing HER2-expressing xenografts","volume":"63","author":"Oroujeni","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2025.02.047_bb0115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/oli.2008.0152","article-title":"Immunological response to peptide nucleic acid and its peptide conjugate targeted to transactivation response (TAR) region of HIV-1 RNA genome","volume":"18","author":"Upadhyay","year":"2008","journal-title":"Oligonucleotides"},{"issue":"10","key":"10.1016\/j.jconrel.2025.02.047_bb0120","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: the architect behind the immune and nonimmune functions of IgG and albumin","volume":"194","author":"Pyzik","year":"2015","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.jconrel.2025.02.047_bb0125","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1021\/acs.molpharmaceut.6b00153","article-title":"Altering antibody-drug conjugate binding to the neonatal Fc receptor impacts efficacy and tolerability","volume":"13","author":"Hamblett","year":"2016","journal-title":"Mol. Pharm."},{"issue":"367","key":"10.1016\/j.jconrel.2025.02.047_bb0130","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2335","article-title":"Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis","volume":"8","author":"Thorek","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2025.02.047_bb0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4161\/mabs.4.1.18543","article-title":"Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice","volume":"4","author":"Deng","year":"2012","journal-title":"MAbs"},{"issue":"11","key":"10.1016\/j.jconrel.2025.02.047_bb0140","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41551-019-0470-8","article-title":"Computationally designed antibody\u2013drug conjugates self-assembled via affinity ligands","volume":"3","author":"Gupta","year":"2019","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2025.02.047_bb0145","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1021\/acsptsci.4c00106","article-title":"Shorter peptide nucleic acid probes improve affibody-mediated peptide nucleic acid-based pretargeting","volume":"2024","author":"Westerlund","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2025.02.047_bb0150","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3390\/cancers13030500","article-title":"Comparative evaluation of novel 177Lu-labeled PNA probes for affibody-mediated PNA-based pretargeting","volume":"13","author":"Tano","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.jconrel.2025.02.047_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41181-024-00273-z","article-title":"In vitro and in vivo evaluation of a tetrazine-conjugated poly-L-lysine effector molecule labeled with astatine-211","volume":"9","author":"Timperanza","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"issue":"8","key":"10.1016\/j.jconrel.2025.02.047_bb0160","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1080\/19420862.2018.1521132","article-title":"Site-specific conjugation allows modulation of click reaction stoichiometry for pretargeted SPECT imaging","volume":"10","author":"Mandikian","year":"2018","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.jconrel.2025.02.047_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-017-0344-6","article-title":"Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models","volume":"7","author":"Kein\u00e4nen","year":"2017","journal-title":"EJNMMI Res."},{"issue":"12","key":"10.1016\/j.jconrel.2025.02.047_bb0170","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1021\/acs.bioconjchem.7b00635","article-title":"Pretargeted PET imaging using a bioorthogonal 18F-labeled trans-cyclooctene in an ovarian carcinoma model","volume":"28","author":"Billaud","year":"2017","journal-title":"Bioconjug. Chem."},{"issue":"7","key":"10.1016\/j.jconrel.2025.02.047_bb0175","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1021\/acs.molpharmaceut.7b00172","article-title":"In vivo pretargeted imaging of HER2 and TAG-72 expression using the HaloTag enzyme","volume":"14","author":"Knight","year":"2017","journal-title":"Mol. Pharm."},{"issue":"18","key":"10.1016\/j.jconrel.2025.02.047_bb0180","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.7150\/thno.26585","article-title":"Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: curative treatment of HER2-positive breast carcinoma","volume":"8","author":"Cheal","year":"2018","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.jconrel.2025.02.047_bb0185","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/ph16040497","article-title":"Clearing and masking agents in pretargeting strategies","volume":"16","author":"Staudt","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.jconrel.2025.02.047_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-77523-y","article-title":"Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting","volume":"10","author":"Myrhammar","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2025.02.047_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph5010001","article-title":"Pre-clinical assessment of 177Lu-labeled trastuzumab targeting HER2 for treatment and management of cancer patients with disseminated intraperitoneal disease","volume":"5","author":"Ray","year":"2011","journal-title":"Pharmaceuticals"},{"issue":"8","key":"10.1016\/j.jconrel.2025.02.047_bb0200","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1021\/acs.bioconjchem.6b00235","article-title":"Pretargeted PET imaging using a site-specifically labeled immunoconjugate","volume":"27","author":"Cook","year":"2016","journal-title":"Bioconjug. Chem."},{"issue":"3","key":"10.1016\/j.jconrel.2025.02.047_bb0205","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2967\/jnumed.115.163824","article-title":"Pretargeted immuno-PET of pancreatic cancer: overcoming circulating antigen and internalized antibody to reduce radiation doses","volume":"57","author":"Houghton","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.jconrel.2025.02.047_bb0210","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.2967\/jnumed.115.159145","article-title":"CC49 diabody pretargeting using click chemistry in vivo","volume":"56","author":"Van Duijnhoven","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.02.047_bb0215","series-title":"Essentials of Veterinary Hematology","first-page":"417","author":"Jain","year":"1993"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925001609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925001609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T01:56:48Z","timestamp":1769219808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925001609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":43,"alternative-id":["S0168365925001609"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.02.047","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing peptide nucleic acid-based pretargeting for enhanced targeted radionuclide therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.02.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113551"}}